Plus, a biotech with a whopping 75% potential upside...
Plus, a hardware giant whose AI backlog forced a target jump from $29 to $74...
One stock pick from a top-ranked analyst with an implied upside of 100% or more.
Plus, the third-best analyst on Wall Street’s 44% upside call.
Plus, a grid intelligence leader with a record $4.4B backlog.
Plus, a Top 1% analyst weighs in on Wall Street's biggest stock.
Plus, a Top 1% UBS stock picker sees almost 50% upside on this chipmaker, and more.
Plus, the 9th best analyst on Wall Street's favorite AI call, and more.
Plus, the latest ticker from a Wall Street analyst with +186% average returns, a Top 1% analyst's take on Tesla, and more.
Plus, a Permian Basin play that just got a 73% PT bump, a GPCR drug developer with 60% upside potential, and more...
Plus, a precision oncology biotech with room to run, a CNS drug challenger with nearly $4B in projected peak sales, and more...
Plus, a top-1% analyst's highest-conviction AI infrastructure bet and the post-IPO software name Goldman says the market is missing out on.
The market may be missing a protein upgrade that favors eggs.
Plus, a firm with three hyperscale leases signed, a biotech with four drugs on market, and a stock down 29% that activists just shook up.
Plus, a chipmaker guiding to 903% earnings growth, a gene therapy stock one top 2% analyst gives 170% upside, and more.
Plus, a quiet winner of the US defense budget, a COVID-era darling due for a resurgence, and a top-tier analyst’s contrarian call carrying more than 100% upside potential.
Plus, a beaten-down enterprise play with more than 100% upside potential, a bitcoin miner with a repositioning plan that caught the eye of a Top 1% analyst, and more.
A below-the-signal beneficiary of the fiber revolution.
Plus, an unexpected beneficiary of a dead deal, a post-AI-selloff dip-buying opportunity, and a high-upside-potential call from an analyst with an average return of more than 80%.
Plus, a beaten-down fintech stock with a favorable risk-reward profile, our Goldman Sachs-backed bull thesis, and Morgan Stanley’s 125% upside data center pick.
Plus, William Blair’s memory “supercycle” winner, a stock Morgan Stanley says has “ongoing execution issues”, Netflix’s new deal, the top IPOs of tomorrow, and more.
Plus, a doubled price target from Aletheia, potential beneficiaries of the latest tariff delay, and much more.
Plus, the mid-cap software stock KeyBanc was wrong about, Goldman Sachs’ semiconductor double-downgrade, and much more.
Plus, dual double-downgrades, a crypto firm with 130% implied upside, and much more.
